Literature DB >> 2551269

ADP and, indirectly, ATP are potent inhibitors of cAMP production in intact isoproterenol-stimulated C6 glioma cells.

I Pianet1, M Merle, J Labouesse.   

Abstract

When added to intact C6 glioma cells in the micromolar range of concentrations, ADP and ATP induce an inhibition of the isoproterenol-elicited cAMP responses. ATP is rapidly hydrolyzed by the ectonucleotidases present on these cells, with an apparent Km of 50 microM and a Vmax of 1.1 nmol/min/10(6) cells. cAMP responses are also inhibited by millimolar concentrations of either ATP in the presence of an ATP-regenerating system to prevent ADP accumulation or AMP-PCP. These observations show that, in C6 glioma cells, ADP is a more potent inhibitor of cAMP production than ATP, the latter acting indirectly, via its rapid hydrolysis to ADP. The additive inhibition of isoproterenol-elicited cAMP responses induced, on one hand, by the treatment of the cells with a phorbol ester and by addition of ADP to the cells, and, on the other hand, by the progressive disappearance of the effects of ADP and ATP when cells are treated with increasing concentrations of Pertussis toxin, demonstrate that ADP and ATP exert their action in C6 glioma cells via a P2 purinoceptor probably negatively coupled to adenylate cyclase and a G regulatory protein.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551269     DOI: 10.1016/0006-291x(89)92341-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

Review 1.  P2 receptor subtypes in the cardiovascular system.

Authors:  S P Kunapuli; J L Daniel
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

2.  Two subtypes of G protein-coupled nucleotide receptors, P2Y(1) and P2Y(2) are involved in calcium signalling in glioma C6 cells.

Authors:  P Sabala; R Czajkowski; K Przybyłek; K Kalita; L Kaczmarek; J Barańska
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

3.  P2 Receptor-mediated Inhibition of Vasopressin-stimulated Fluid Transport and cAMP Responses in AQP2-transfected MDCK Cells.

Authors:  Yang Hoo Kim; Young Jin Choi; Hae Rahn Bae; Jae Suk Woo
Journal:  Korean J Physiol Pharmacol       Date:  2009-02-28       Impact factor: 2.016

4.  SYNTHESIS AND BIOLOGICAL ACTIVITY OF NOVEL 2-THIO DERIVATIVES OF ATP.

Authors:  J Zimmet; L Järlebark; T Hammarberg; P J M van Galen; K A Jacobson; E Heilbronn
Journal:  Nucleosides Nucleotides       Date:  1993

5.  The C6-2B glioma cell P2Y(AC) receptor is pharmacologically and molecularly identical to the platelet P2Y(12) receptor.

Authors:  J Jin; W Tomlinson; I P Kirk; Y B Kim; R G Humphries; S P Kunapuli
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

6.  Ecto-nucleotide pyrophosphatase modulates the purinoceptor-mediated signal transduction and is inhibited by purinoceptor antagonists.

Authors:  B Grobben; P Claes; D Roymans; E L Esmans; H Van Onckelen; H Slegers
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

7.  Extracellular ATP stimulates inositol phospholipid turnover and calcium influx in C6 glioma cells.

Authors:  W W Lin; D M Chuang
Journal:  Neurochem Res       Date:  1993-06       Impact factor: 3.996

8.  Potent agonist action of 2-thioether derivatives of adenine nucleotides at adenylyl cyclase-linked P2Y-purinoceptors.

Authors:  J L Boyer; J W O'Tuel; B Fischer; K A Jacobson; T K Harden
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

9.  Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors.

Authors:  J L Boyer; I E Zohn; K A Jacobson; T K Harden
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

10.  Contribution of the phosphorylable complex I in the growth phase-dependent respiration of C6 glioma cells in vitro.

Authors:  P Pasdois; C Deveaud; P Voisin; V Bouchaud; M Rigoulet; B Beauvoit
Journal:  J Bioenerg Biomembr       Date:  2003-10       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.